
    
      A single center, phase II randomized, double-blind, placebo-controlled, cross-over study
      designed to assess the efficacy and safety of intranasally (IN) delivered insulin glulisine
      versus placebo in patients aged 65-85 with mild-moderate Alzheimer's Disease (AD). Twelve AD
      subjects (six female and six male) will be randomized to receive a single dose of either 20
      IU/IN insulin glulisine or placebo using the MAD 300 device.
    
  